細胞分析市場(エンドユーザー:バイオテクノロジー・製薬企業、アカデミア、化粧品業界、研究受託機関、開発・製造受託機関) - 世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年Cell Analysis Market (End-user: Biotechnology & Pharmaceutical Companies, Academia, Cosmetic Industry, Contract Research Organizations, and Contract Development & Manufacturing Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 細胞分析市場 - レポートの範囲 TMRの調査レポート「世界の細胞分析市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会について... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー細胞分析市場 - レポートの範囲TMRの調査レポート「世界の細胞分析市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の細胞分析市場の収益を掲載しています。また、2023年から2031年までの世界の細胞分析市場の複合年間成長率(CAGR %)も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、細胞分析市場を理解しました。 二次調査には、インターネットソース、政府機関の統計データ、ウェブサイト、業界団体も含まれる。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の細胞分析市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれるさまざまなセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、このレポートは世界の細胞分析市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界の細胞分析市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートでは、世界の細胞分析市場の競争環境について掘り下げています。世界の細胞分析市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界の細胞分析市場におけるプレイヤーの属性である。 細胞分析の世界市場レポートが回答した主な質問 - 予測期間中の全地域における細胞分析が生み出す売上/収益は? - 世界の細胞分析市場におけるビジネスチャンスは? - 市場の主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは? - 世界市場で事業を展開する各企業の市場ポジションは? 細胞分析市場 - 調査目的と調査アプローチ 世界の細胞分析市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳細に解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。 本レポートでは、世界の細胞分析市場を製品、エンドユーザー、地域の観点から分析している。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の細胞分析市場への投資について十分な情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Key Research Objectives 2. Assumptions and Research Methodology 3. Market Overview 3.1. Overview 3.2. Market Dynamics 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Opportunities 3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area 3.3.1. Top 15 Origins of Pipeline Drugs 3.3.2. Biological versus non-biological drugs as a % of pipeline 3.3.3. Ongoing rise of gene and cell therapy 4. Global Cell Analysis Market Analysis and Forecast, by End-user 4.1. Introduction & Definition 4.2. Key Findings/Developments 4.3. Market Value Forecast, by End-user, 2017-2031 4.3.1. Biotechnology & Pharmaceutical Companies 4.3.2. Academia 4.3.3. Cosmetic Industry 4.3.4. Contract Research Organizations 4.3.5. Contract Development and Manufacturing Organizations 5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area 5.1. Introduction & Definition 5.2. Key Findings/Developments 5.3. Market Value Forecast, by Therapeutic Area, 2015-2031 5.3.1. Oncology & Immune-oncology 5.3.1.1. Small Molecules 5.3.1.2. Protein-based Therapeutics 5.3.1.3. Cell Therapy 5.3.1.4. Nucleic Acid-based Drugs 5.3.2. Cardiovascular & Metabolic Diseases 5.3.2.1. Small Molecules 5.3.2.2. Protein-based Therapeutics 5.3.2.3. Cell Therapy 5.3.2.4. Nucleic Acid-based Drugs 5.3.3. Immunology 5.3.3.1. Small Molecules 5.3.3.2. Protein-based Therapeutics 5.3.3.3. Cell Therapy 5.3.3.4. Nucleic Acid-based Drugs 5.3.4. Rare Diseases 5.3.4.1. Small Molecules 5.3.4.2. Protein-based Therapeutics 5.3.4.3. Cell Therapy 5.3.4.4. Nucleic Acid-based Drugs 5.3.5. Neurological Diseases 5.3.5.1. Small Molecules 5.3.5.2. Protein-based Therapeutics 5.3.5.3. Cell Therapy 5.3.5.4. Nucleic Acid-based Drugs 5.3.6. Others 5.3.6.1. Small Molecules 5.3.6.2. Protein-based Therapeutics 5.3.6.3. Cell Therapy 5.3.6.4. Nucleic Acid-based Drugs 6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Technology, 2017-2031 6.3.1. Flow Cytometry 6.3.2. Image-based Cytometry 6.3.3. Biochemical Assays 6.3.4. Mass Spectrometry 7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Workplace, 2017-2031 7.3.1. Target Identification 7.3.2. Hit Generation & Lead Identification 7.3.3. Lead Optimization 7.3.4. In Vitro Preclinical Studies 7.3.5. In Vivo Preclinical Studies 7.3.6. Clinical Studies 8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region 8.1. Key Findings 8.2. Market Value Forecast, by Country/Region, 2017-2031 8.2.1. U.S. 8.2.2. Europe 8.2.3. China 8.2.4. Rest of the World 9. U.S. Cell Analysis Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. Market Value Forecast, by End-user, 2017-2031 9.2.1. Biotechnology & Pharmaceutical Companies 9.2.2. Academia 9.2.3. Cosmetic Industry 9.2.4. Contract Research Organizations 9.2.5. Contract Development and Manufacturing Organizations 9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 9.3.1. Oncology & Immune-oncology 9.3.1.1. Small Molecules 9.3.1.2. Protein-based Therapeutics 9.3.1.3. Cell Therapy 9.3.1.4. Nucleic Acid-based Drugs 9.3.2. Cardiovascular & Metabolic Diseases 9.3.2.1. Small Molecules 9.3.2.2. Protein-based Therapeutics 9.3.2.3. Cell Therapy 9.3.2.4. Nucleic Acid-based Drugs 9.3.3. Immunology 9.3.3.1. Small Molecules 9.3.3.2. Protein-based Therapeutics 9.3.3.3. Cell Therapy 9.3.3.4. Nucleic Acid-based Drugs 9.3.4. Rare Diseases 9.3.4.1. Small Molecules 9.3.4.2. Protein-based Therapeutics 9.3.4.3. Cell Therapy 9.3.4.4. Nucleic Acid-based Drugs 9.3.5. Neurological Diseases 9.3.5.1. Small Molecules 9.3.5.2. Protein-based Therapeutics 9.3.5.3. Cell Therapy 9.3.5.4. Nucleic Acid-based Drugs 9.3.6. Others 9.3.6.1. Small Molecules 9.3.6.2. Protein-based Therapeutics 9.3.6.3. Cell Therapy 9.3.6.4. Nucleic Acid-based Drugs 9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 9.4.1. Flow Cytometry 9.4.2. Image-based Cytometry 9.4.3. Biochemical Assays 9.4.4. Mass Spectrometry 9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 9.5.1. Target Identification 9.5.2. Hit Generation & Lead Identification 9.5.3. Lead Optimization 9.5.4. In Vitro Preclinical Studies 9.5.5. In Vivo Preclinical Studies 9.5.6. Clinical Studies 10. Europe Cell Analysis Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by End-user, 2017-2031 10.2.1. Biotechnology & Pharmaceutical Companies 10.2.2. Academia 10.2.3. Cosmetic Industry 10.2.4. Contract Research Organizations 10.2.5. Contract Development and Manufacturing Organizations 10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 10.3.1. Oncology & Immune-oncology 10.3.1.1. Small Molecules 10.3.1.2. Protein-based Therapeutics 10.3.1.3. Cell Therapy 10.3.1.4. Nucleic Acid-based Drugs 10.3.2. Cardiovascular & Metabolic Diseases 10.3.2.1. Small Molecules 10.3.2.2. Protein-based Therapeutics 10.3.2.3. Cell Therapy 10.3.2.4. Nucleic Acid-based Drugs 10.3.3. Immunology 10.3.3.1. Small Molecules 10.3.3.2. Protein-based Therapeutics 10.3.3.3. Cell Therapy 10.3.3.4. Nucleic Acid-based Drugs 10.3.4. Rare Diseases 10.3.4.1. Small Molecules 10.3.4.2. Protein-based Therapeutics 10.3.4.3. Cell Therapy 10.3.4.4. Nucleic Acid-based Drugs 10.3.5. Neurological Diseases 10.3.5.1. Small Molecules 10.3.5.2. Protein-based Therapeutics 10.3.5.3. Cell Therapy 10.3.5.4. Nucleic Acid-based Drugs 10.3.6. Others 10.3.6.1. Small Molecules 10.3.6.2. Protein-based Therapeutics 10.3.6.3. Cell Therapy 10.3.6.4. Nucleic Acid-based Drugs 10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 10.4.1. Flow Cytometry 10.4.2. Image-based Cytometry 10.4.3. Biochemical Assays 10.4.4. Mass Spectrometry 10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 10.5.1. Target Identification 10.5.2. Hit Generation & Lead Identification 10.5.3. Lead Optimization 10.5.4. In Vitro Preclinical Studies 10.5.5. In Vivo Preclinical Studies 10.5.6. Clinical Studies 10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031 10.6.1. EU5 10.6.2. U.K. 10.6.3. Switzerland 10.6.4. Rest of Europe 11. China Cell Analysis Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by End-user, 2017-2031 11.2.1. Biotechnology & Pharmaceutical Companies 11.2.2. Academia 11.2.3. Cosmetic Industry 11.2.4. Contract Research Organizations 11.2.5. Contract Development and Manufacturing Organizations 11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 11.3.1. Oncology & Immune-oncology 11.3.1.1. Small Molecules 11.3.1.2. Protein-based Therapeutics 11.3.1.3. Cell Therapy 11.3.1.4. Nucleic Acid-based Drugs 11.3.2. Cardiovascular & Metabolic Diseases 11.3.2.1. Small Molecules 11.3.2.2. Protein-based Therapeutics 11.3.2.3. Cell Therapy 11.3.2.4. Nucleic Acid-based Drugs 11.3.3. Immunology 11.3.3.1. Small Molecules 11.3.3.2. Protein-based Therapeutics 11.3.3.3. Cell Therapy 11.3.3.4. Nucleic Acid-based Drugs 11.3.4. Rare Diseases 11.3.4.1. Small Molecules 11.3.4.2. Protein-based Therapeutics 11.3.4.3. Cell Therapy 11.3.4.4. Nucleic Acid-based Drugs 11.3.5. Neurological Diseases 11.3.5.1. Small Molecules 11.3.5.2. Protein-based Therapeutics 11.3.5.3. Cell Therapy 11.3.5.4. Nucleic Acid-based Drugs 11.3.6. Others 11.3.6.1. Small Molecules 11.3.6.2. Protein-based Therapeutics 11.3.6.3. Cell Therapy 11.3.6.4. Nucleic Acid-based Drugs 11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 11.4.1. Flow Cytometry 11.4.2. Image-based Cytometry 11.4.3. Biochemical Assays 11.4.4. Mass Spectrometry 11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 11.5.1. Target Identification 11.5.2. Hit Generation & Lead Identification 11.5.3. Lead Optimization 11.5.4. In Vitro Preclinical Studies 11.5.5. In Vivo Preclinical Studies 11.5.6. Clinical Studies 12. Rest of the World Cell Analysis Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by End-user, 2017-2031 12.2.1. Biotechnology & Pharmaceutical Companies 12.2.2. Academia 12.2.3. Cosmetic Industry 12.2.4. Contract Research Organizations 12.2.5. Contract Development and Manufacturing Organizations 12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 12.3.1. Oncology & Immune-oncology 12.3.1.1. Small Molecules 12.3.1.2. Protein-based Therapeutics 12.3.1.3. Cell Therapy 12.3.1.4. Nucleic Acid-based Drugs 12.3.2. Cardiovascular & Metabolic Diseases 12.3.2.1. Small Molecules 12.3.2.2. Protein-based Therapeutics 12.3.2.3. Cell Therapy 12.3.2.4. Nucleic Acid-based Drugs 12.3.3. Immunology 12.3.3.1. Small Molecules 12.3.3.2. Protein-based Therapeutics 12.3.3.3. Cell Therapy 12.3.3.4. Nucleic Acid-based Drugs 12.3.4. Rare Diseases 12.3.4.1. Small Molecules 12.3.4.2. Protein-based Therapeutics 12.3.4.3. Cell Therapy 12.3.4.4. Nucleic Acid-based Drugs 12.3.5. Neurological Diseases 12.3.5.1. Small Molecules 12.3.5.2. Protein-based Therapeutics 12.3.5.3. Cell Therapy 12.3.5.4. Nucleic Acid-based Drugs 12.3.6. Others 12.3.6.1. Small Molecules 12.3.6.2. Protein-based Therapeutics 12.3.6.3. Cell Therapy 12.3.6.4. Nucleic Acid-based Drugs 12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 12.4.1. Flow Cytometry 12.4.2. Image-based Cytometry 12.4.3. Biochemical Assays 12.4.4. Mass Spectrometry 12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 12.5.1. Target Identification 12.5.2. Hit Generation & Lead Identification 12.5.3. Lead Optimization 12.5.4. In Vitro Preclinical Studies 12.5.5. In Vivo Preclinical Studies 12.5.6. Clinical Studies
SummaryCell Analysis Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Key Research Objectives 2. Assumptions and Research Methodology 3. Market Overview 3.1. Overview 3.2. Market Dynamics 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Opportunities 3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area 3.3.1. Top 15 Origins of Pipeline Drugs 3.3.2. Biological versus non-biological drugs as a % of pipeline 3.3.3. Ongoing rise of gene and cell therapy 4. Global Cell Analysis Market Analysis and Forecast, by End-user 4.1. Introduction & Definition 4.2. Key Findings/Developments 4.3. Market Value Forecast, by End-user, 2017-2031 4.3.1. Biotechnology & Pharmaceutical Companies 4.3.2. Academia 4.3.3. Cosmetic Industry 4.3.4. Contract Research Organizations 4.3.5. Contract Development and Manufacturing Organizations 5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area 5.1. Introduction & Definition 5.2. Key Findings/Developments 5.3. Market Value Forecast, by Therapeutic Area, 2015-2031 5.3.1. Oncology & Immune-oncology 5.3.1.1. Small Molecules 5.3.1.2. Protein-based Therapeutics 5.3.1.3. Cell Therapy 5.3.1.4. Nucleic Acid-based Drugs 5.3.2. Cardiovascular & Metabolic Diseases 5.3.2.1. Small Molecules 5.3.2.2. Protein-based Therapeutics 5.3.2.3. Cell Therapy 5.3.2.4. Nucleic Acid-based Drugs 5.3.3. Immunology 5.3.3.1. Small Molecules 5.3.3.2. Protein-based Therapeutics 5.3.3.3. Cell Therapy 5.3.3.4. Nucleic Acid-based Drugs 5.3.4. Rare Diseases 5.3.4.1. Small Molecules 5.3.4.2. Protein-based Therapeutics 5.3.4.3. Cell Therapy 5.3.4.4. Nucleic Acid-based Drugs 5.3.5. Neurological Diseases 5.3.5.1. Small Molecules 5.3.5.2. Protein-based Therapeutics 5.3.5.3. Cell Therapy 5.3.5.4. Nucleic Acid-based Drugs 5.3.6. Others 5.3.6.1. Small Molecules 5.3.6.2. Protein-based Therapeutics 5.3.6.3. Cell Therapy 5.3.6.4. Nucleic Acid-based Drugs 6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Technology, 2017-2031 6.3.1. Flow Cytometry 6.3.2. Image-based Cytometry 6.3.3. Biochemical Assays 6.3.4. Mass Spectrometry 7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Workplace, 2017-2031 7.3.1. Target Identification 7.3.2. Hit Generation & Lead Identification 7.3.3. Lead Optimization 7.3.4. In Vitro Preclinical Studies 7.3.5. In Vivo Preclinical Studies 7.3.6. Clinical Studies 8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region 8.1. Key Findings 8.2. Market Value Forecast, by Country/Region, 2017-2031 8.2.1. U.S. 8.2.2. Europe 8.2.3. China 8.2.4. Rest of the World 9. U.S. Cell Analysis Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. Market Value Forecast, by End-user, 2017-2031 9.2.1. Biotechnology & Pharmaceutical Companies 9.2.2. Academia 9.2.3. Cosmetic Industry 9.2.4. Contract Research Organizations 9.2.5. Contract Development and Manufacturing Organizations 9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 9.3.1. Oncology & Immune-oncology 9.3.1.1. Small Molecules 9.3.1.2. Protein-based Therapeutics 9.3.1.3. Cell Therapy 9.3.1.4. Nucleic Acid-based Drugs 9.3.2. Cardiovascular & Metabolic Diseases 9.3.2.1. Small Molecules 9.3.2.2. Protein-based Therapeutics 9.3.2.3. Cell Therapy 9.3.2.4. Nucleic Acid-based Drugs 9.3.3. Immunology 9.3.3.1. Small Molecules 9.3.3.2. Protein-based Therapeutics 9.3.3.3. Cell Therapy 9.3.3.4. Nucleic Acid-based Drugs 9.3.4. Rare Diseases 9.3.4.1. Small Molecules 9.3.4.2. Protein-based Therapeutics 9.3.4.3. Cell Therapy 9.3.4.4. Nucleic Acid-based Drugs 9.3.5. Neurological Diseases 9.3.5.1. Small Molecules 9.3.5.2. Protein-based Therapeutics 9.3.5.3. Cell Therapy 9.3.5.4. Nucleic Acid-based Drugs 9.3.6. Others 9.3.6.1. Small Molecules 9.3.6.2. Protein-based Therapeutics 9.3.6.3. Cell Therapy 9.3.6.4. Nucleic Acid-based Drugs 9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 9.4.1. Flow Cytometry 9.4.2. Image-based Cytometry 9.4.3. Biochemical Assays 9.4.4. Mass Spectrometry 9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 9.5.1. Target Identification 9.5.2. Hit Generation & Lead Identification 9.5.3. Lead Optimization 9.5.4. In Vitro Preclinical Studies 9.5.5. In Vivo Preclinical Studies 9.5.6. Clinical Studies 10. Europe Cell Analysis Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by End-user, 2017-2031 10.2.1. Biotechnology & Pharmaceutical Companies 10.2.2. Academia 10.2.3. Cosmetic Industry 10.2.4. Contract Research Organizations 10.2.5. Contract Development and Manufacturing Organizations 10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 10.3.1. Oncology & Immune-oncology 10.3.1.1. Small Molecules 10.3.1.2. Protein-based Therapeutics 10.3.1.3. Cell Therapy 10.3.1.4. Nucleic Acid-based Drugs 10.3.2. Cardiovascular & Metabolic Diseases 10.3.2.1. Small Molecules 10.3.2.2. Protein-based Therapeutics 10.3.2.3. Cell Therapy 10.3.2.4. Nucleic Acid-based Drugs 10.3.3. Immunology 10.3.3.1. Small Molecules 10.3.3.2. Protein-based Therapeutics 10.3.3.3. Cell Therapy 10.3.3.4. Nucleic Acid-based Drugs 10.3.4. Rare Diseases 10.3.4.1. Small Molecules 10.3.4.2. Protein-based Therapeutics 10.3.4.3. Cell Therapy 10.3.4.4. Nucleic Acid-based Drugs 10.3.5. Neurological Diseases 10.3.5.1. Small Molecules 10.3.5.2. Protein-based Therapeutics 10.3.5.3. Cell Therapy 10.3.5.4. Nucleic Acid-based Drugs 10.3.6. Others 10.3.6.1. Small Molecules 10.3.6.2. Protein-based Therapeutics 10.3.6.3. Cell Therapy 10.3.6.4. Nucleic Acid-based Drugs 10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 10.4.1. Flow Cytometry 10.4.2. Image-based Cytometry 10.4.3. Biochemical Assays 10.4.4. Mass Spectrometry 10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 10.5.1. Target Identification 10.5.2. Hit Generation & Lead Identification 10.5.3. Lead Optimization 10.5.4. In Vitro Preclinical Studies 10.5.5. In Vivo Preclinical Studies 10.5.6. Clinical Studies 10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031 10.6.1. EU5 10.6.2. U.K. 10.6.3. Switzerland 10.6.4. Rest of Europe 11. China Cell Analysis Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by End-user, 2017-2031 11.2.1. Biotechnology & Pharmaceutical Companies 11.2.2. Academia 11.2.3. Cosmetic Industry 11.2.4. Contract Research Organizations 11.2.5. Contract Development and Manufacturing Organizations 11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 11.3.1. Oncology & Immune-oncology 11.3.1.1. Small Molecules 11.3.1.2. Protein-based Therapeutics 11.3.1.3. Cell Therapy 11.3.1.4. Nucleic Acid-based Drugs 11.3.2. Cardiovascular & Metabolic Diseases 11.3.2.1. Small Molecules 11.3.2.2. Protein-based Therapeutics 11.3.2.3. Cell Therapy 11.3.2.4. Nucleic Acid-based Drugs 11.3.3. Immunology 11.3.3.1. Small Molecules 11.3.3.2. Protein-based Therapeutics 11.3.3.3. Cell Therapy 11.3.3.4. Nucleic Acid-based Drugs 11.3.4. Rare Diseases 11.3.4.1. Small Molecules 11.3.4.2. Protein-based Therapeutics 11.3.4.3. Cell Therapy 11.3.4.4. Nucleic Acid-based Drugs 11.3.5. Neurological Diseases 11.3.5.1. Small Molecules 11.3.5.2. Protein-based Therapeutics 11.3.5.3. Cell Therapy 11.3.5.4. Nucleic Acid-based Drugs 11.3.6. Others 11.3.6.1. Small Molecules 11.3.6.2. Protein-based Therapeutics 11.3.6.3. Cell Therapy 11.3.6.4. Nucleic Acid-based Drugs 11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 11.4.1. Flow Cytometry 11.4.2. Image-based Cytometry 11.4.3. Biochemical Assays 11.4.4. Mass Spectrometry 11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 11.5.1. Target Identification 11.5.2. Hit Generation & Lead Identification 11.5.3. Lead Optimization 11.5.4. In Vitro Preclinical Studies 11.5.5. In Vivo Preclinical Studies 11.5.6. Clinical Studies 12. Rest of the World Cell Analysis Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by End-user, 2017-2031 12.2.1. Biotechnology & Pharmaceutical Companies 12.2.2. Academia 12.2.3. Cosmetic Industry 12.2.4. Contract Research Organizations 12.2.5. Contract Development and Manufacturing Organizations 12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031 12.3.1. Oncology & Immune-oncology 12.3.1.1. Small Molecules 12.3.1.2. Protein-based Therapeutics 12.3.1.3. Cell Therapy 12.3.1.4. Nucleic Acid-based Drugs 12.3.2. Cardiovascular & Metabolic Diseases 12.3.2.1. Small Molecules 12.3.2.2. Protein-based Therapeutics 12.3.2.3. Cell Therapy 12.3.2.4. Nucleic Acid-based Drugs 12.3.3. Immunology 12.3.3.1. Small Molecules 12.3.3.2. Protein-based Therapeutics 12.3.3.3. Cell Therapy 12.3.3.4. Nucleic Acid-based Drugs 12.3.4. Rare Diseases 12.3.4.1. Small Molecules 12.3.4.2. Protein-based Therapeutics 12.3.4.3. Cell Therapy 12.3.4.4. Nucleic Acid-based Drugs 12.3.5. Neurological Diseases 12.3.5.1. Small Molecules 12.3.5.2. Protein-based Therapeutics 12.3.5.3. Cell Therapy 12.3.5.4. Nucleic Acid-based Drugs 12.3.6. Others 12.3.6.1. Small Molecules 12.3.6.2. Protein-based Therapeutics 12.3.6.3. Cell Therapy 12.3.6.4. Nucleic Acid-based Drugs 12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031 12.4.1. Flow Cytometry 12.4.2. Image-based Cytometry 12.4.3. Biochemical Assays 12.4.4. Mass Spectrometry 12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031 12.5.1. Target Identification 12.5.2. Hit Generation & Lead Identification 12.5.3. Lead Optimization 12.5.4. In Vitro Preclinical Studies 12.5.5. In Vivo Preclinical Studies 12.5.6. Clinical Studies
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Transparency Market Research社の医療分野での最新刊レポート
本レポートと同じKEY WORD(analysis market)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |